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Abstract
Background: Breast carcinomas with neuroendocrine features (NEBC) are a very rare entity of mammary neoplasms,
WHO classification of which has recently been revised. There are very limited data available about the clinical
behaviour and treatment options of NEBC.
Methods: We collected retrospectively patients with NEBC from Oulu and Helsinki University Hospitals in 2007–2015.
There were 43 NEBC cases during the period.
Results: The incidence of NEBC from all breast cancers varied from 0.1% in Helsinki to 1.3% in Oulu. The mean tumor
size was 2.2 cm and 23 patients (55.8%) had no lymph node metastases when diagnosed. In total, 4 patients (9.3%) had
distant metastases at the time of diagnosis. High estrogen receptor (ER) expression was observed in 41 (97.7%)
patients. When non-metastatic NEBC were compared to a prospective set of ductal carcinomas (n = 506), NEBC
were more often HER2 negative (p = 0.046), ER positive (p = 0.0062) and the NEBC patients were older (p < 0.0005)
than patients with ductal carcinomas. Plasma chromogranin A correlated only to higher age at diagnosis (p = 0.
0028). Relapse-free survival (p = 0.0013), disease-free survival (p = 0.024) and overall survival (p = 0.0028) favoured
ductal carcinomas compared to NEBC, while no difference was observed in distant disease-free survival or in
breast cancer-specific survival.
Conclusions: There is remarkable variation in the incidence of NEBC in Finland, which is likely to be explained by
differences in the use of neuroendocrine marker immunostainings. Poor local control and worse overall survival may be
linked to the more aggressive biology of the disease, despite its association with apparently indolent prognostic factors.
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Background
Breast carcinomas with neuroendocrine features (NEBC)
are usually estimated to represent <1% of all breast cancers
[1, 2]. Their actual incidence is in fact difficult to assess
since neuroendocrine markers (NE) are not routinely used
in breast cancer diagnostics and NEBC are challenging to
recognize clinically or with basic immunohistochemistry.
The World Health Organization (WHO) definition for
breast cancer with neuroendocrine features has been re-
vised lately [1, 3]. According to the definition of 2012, there
is no specific threshold for the positivity of neuroendocrine
marker expression, namely synaptophysin or chromogra-
nin but either expression is required for the diagnosis. Ac-
cording to WHO, chromogranin and synaptophysin
expression may significantly vary, depending e.g. on the
grade. The latest WHO diagnostic criteria for NEBC also
emphasize the reliable exclusion of the possibility of meta-
static neuroendocrine/small-cell carcinoma before a defin-
ite diagnosis since ≥97% of all neuroendocrine carcinomas
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derive from lungs or gastrointestinal tract [4]. The pres-
ence of ductal carcinoma in situ (DCIS) is supportive of
origin in the breast [1]. Clinically and macroscopically
NEBCs are indistinguishable from other tumour types [1].
According to the most common theory, NEBC are
thought to originate from neoplastic epithelial cells dur-
ing the carcinogenesis [5]. There might still be prognos-
tic and predictive differences between the NEBC and
ductal carcinomas – some papers using older criteria for
NEBC have suggested different biological profile and
maybe also poorer prognosis of the patients with NEBC
[6, 7]. Data from small series suggest that NEBC com-
prise a discrete molecular cluster [8]. When a large set
of mucinous breast carcinomas were compared with
NEBCs, hypercellular mucinous B type tumours had a
very close profile both in hierarchical clustering analysis
and in transcriptomic analysis. In contrast, grade- and
molecular subtype-matched invasive ductal carcinomas
were transcriptionally distinct from NEBCs [9]. Some
NEBC also harbour potentially actionable oncogene mu-
tations such as PI3KCA, FGRF and RAS mutations [8].
We collected retrospectively NEBC cases and their
clinicopathological data from two Finnish University
Hospitals from the past 8.5 years. Special emphasis was
given to follow the current WHO criteria for NEBC, in
particular the exclusion of primary tumor from extra-
mammary sites and adequate NE marker expression.
Our primary aim was to compare the prognostic factor
profile of NEBC to the prospective contemporary set of
ductal carcinomas. Collection of NEBC cases from two
large hospitals also allowed us to assess the possible dif-
ferences in the incidence of NEBC within the country.
Methods
We collected retrospectively patients diagnosed with
NEBC from Oulu and Helsinki University Hospitals. The
electronic database of the Departments of Pathology was
searched from January 2007 (database launch) to July
2015 using the same criteria in both hospitals. To ex-
clude extramammary origin of carcinoma, the cases
without either 1) both abdominal and thoracic imaging
at the time of diagnosis or 2) histological identification
of ductal in situ carcinoma (DCIS) component were ex-
cluded [1]. Patient data was collected from the medical
records of Oulu and Helsinki University Hospitals. The
comparison group consisted of 506 local or locally ad-
vanced ductal invasive carcinomas from the prospective
cohort diagnosed and treated in Oulu University Hospital
in 2003–2011.
The histopathology of ductal carcinomas was evalu-
ated after current WHO classification and patients were
classed after their TNM classification [1]. Estrogen re-
ceptor (ER), progesterone receptor (PR) and Ki-67 ex-
pressions were studied by immunohistochemistry as
described previously [10]. Grading of NEBC was omitted
as suggested by WHO criteria [1]. HER2 expression was
studied by immunohistochemistry and when HER2-
positive result appeared, gene amplification status was
determined using chromogenic in situ hybridization.
Cancers with six or more gene copies were considered
HER2 positive [11]. Plasma chromogranin A (CgA) was
measured radioimmunologically at the time of diagnosis
in 15 NEBC patients. Synaptophysin and chromogranin
immunohistochemical expression was considered posi-
tive when there was expression of either marker in >50%
of tumor cells.
Statistical analyses
Statistical analysis was performed using IBM SPSS Statis-
tics software, v. 22.0.0.0 (IBM Corporation, Armonk, NY,
USA). The significance of associations was defined by
using two-sided Pearson's Chi-square test or Fisher's exact
test if available. Mann Whitney U test was used when
assessing the continuous variables (age or plasma CgA).
Spearman’s test with correlation coefficient was applied
when correlating plasma CgA to age. Kaplan–Meier
curves with the log-rank test were applied in survival
analysis. Disease-free (DFS), relapse-free (RFS), distant
disease-free (DDFS), breast cancer-specific (BCSS) and
overall (OS) survival were calculated from the time of
diagnosis to disease recurrence at any site (DFS), in the
ipsilateral breast, scar, or axilla (RFS), at distant sites
(DDFS) or to the time of confirmed breast cancer-
related death (BCSS) or time of death from any reason
(OS). In statistical analysis, p-values less than 0.05 were
considered significant.
Results
Our search identified 43 patients fulfilling the latest WHO
criteria for NEBC. Out of them, 12 patients were found
from Helsinki University Hospital and 31 from Oulu Uni-
versity Hospital. In total 4 patients had distant metastases
at the time of the diagnosis, all in bone (Table 1). These
primarily metastasized patients were later excluded from
the analysis when set against local or locally advanced
ductal carcinomas. The mean follow-up time of NEBC
was 35.4 months (95% CI 23.5-47.2 months).
All (100%) identified patients with neuroendocrine
carcinoma had synaptophysin expression >50% of tumor
cells, while 30 tumors (69.8%) showed CgA expression.
Altogether 30 tumors had a histological diagnosis of
DCIS. Both thoracic and abdominal imaging had been
performed preoperatively for 28 patients. All patients
had either preoperative thoracic and abdominal imaging
or a histological diagnosis of DCIS. No evidence of
extramammary primary neuroendocrine tumor sites
arose during the follow-up.
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Clinical and pathological data of the 43 patients with
NEBC are described in Table 1. Five patients had a history
of earlier breast cancer. From all the NEBC patients, 19
(44.2%) were operated with mastectomy and axillary
evacuation, 11 (25.6%) with partial breast resection and
sentinel lymph node biopsy and 6 (14.0%) with mastec-
tomy and sentinel biopsy. Six patients (14.0%) were oper-
ated with other techniques while one patient was not
operated during the follow-up. Thirteen (30.3%) of NEBC
patients received adjuvant chemotherapy, 7 having re-
ceived anthracycline and taxane-based regimen, 3 only
anthracycline-based regimen (CEF) and 3 patients were
treated with other regimens. Two patients (4.7%) received
trastuzumab. Thirty-two (74.4%) had postoperative radio-
therapy and 33 (76.7%) adjuvant endocrine therapy, two of
them tamoxifen and 31 aromatase inhibitor. Three pa-
tients (7.6% of non-metastatic patients) suffered ipsilateral
local recurrence during the follow-up, one in axilla, one in
mastectomy scar and one in the remaining breast. Distant
metastases were not detected at the time of diagnosis. All
these patients received adjuvant radiotherapy.
Thirty-nine non-metastatic NEBC were compared to
506 prospectively collected ductal invasive carcinomas with
no distant metastases present at the time of diagnosis
(Table 2). HER2 was significantly more often negative
(94.9%) in NEBC than in ductal carcinomas (86.4%) (p =
0.046). All except one NEBC showed strong ER positivity
(p = 0.0062 compared to ductal carcinomas), one case be-
ing triple negative (both ER and PR expression 0%). Ki-67
expression was not significantly different in patients with
NEBC or ductal carcinoma (cut-off 15%; p = 0.06). The pa-
tients with NEBC were older than patients with ductal in-
vasive carcinomas (p < 0.0005). All except two patients
with NEBC were postmenopausal at the time of diagnosis.
Fasting plasma CgA levels (median 3.3 nmol/l; range 2.4-
9.9 nmol/l) did not correlate to TNM classification, steroid
receptor status or HER2 status in NEBC patients. Never-
theless, it correlated with higher age at the time of diagnosis
(Spearman’s test p = 0.003, correlation coefficient 0.703)
Table 1 Clinicopathological characteristics of neuroendocrine
carcinomas at the time of diagnosis (n = 43)
Median age (years) 66.0
Menopausal status
Premenopausal 2 (4.7%)
Postmenopausal 39 (90.7%)
Not confirmed 2 (4.7%)
T class
T1 29 (67.4%)
T2 11 (25.6%)
T3 2 (4.7%)
T4 1 (2.3%)
Mean size of primary tumor, mm (95% CI) 25.3 (18.9-31.7)
N class
N0 24 (55.8%)
N1 10 (23.3%)
N2 5 (11.6%)
N3 2 (4.7%)
Missing 2 (4.7%)
Mean number of lymph node metastases (95% CI) 2.2 (0.4-3.9)
Primary distant metastases
No 39 (90.7%)
Yes 4 (9.3%)
HER2 expression
Negative 40 (93.0%)
Positive 2 (4.7%)
Missing 1 (2.3%)
Estrogen receptor expression
Negative (0%) 1 (2.3%)
Low (1-9%) 0 (0%)
Moderate (10-59%) 0 (0%)
High (>60%) 41 (97.7%)
Missing 1 (2.3%)
Progesterone receptor expression
Negative (0%) 4 (9.3%)
Low (1-9%) 6 (14.0%)
Moderate (10-59%) 6 (14.0%)
High (>60%) 25 (58.1%)
Missing 2 (4.7%)
Ki-67 expression
Negative (<5%) 1 (2.3%)
Low (5-14%) 14 (32.6%)
Moderate (15-30%) 15 (34.9%)
High (>30%) 11 (25.6%)
Missing 2 (4.7%)
Table 1 Clinicopathological characteristics of neuroendocrine
carcinomas at the time of diagnosis (n = 43) (Continued)
Multifocal disease
Yes 15 (35.9%)
No 28 (65.1%)
Synaptophysin expression
Yes 43 (100%)
No 0 (0%)
Chromogranin expression
Yes 30 (69.8%)
No 9 (20.9%)
Not available 4 (9.3%)
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Table 2 Neuroendocrine breast carcinomas compared to the prospective set of ductal carcinomas
NEBC (n = 39) Ductal carcinomas (n = 506) p-value
Median age at diagnosis 66.0 57.0 <0.0005
T class 0.40
T1 28 (71.8%) 322 (63.6%)
T2 9 (23.1%) 167 (33.0%)
T3 2 (5.1%) 12 (2.4%)
T4 0 (0.0%) 5 (1.0%)
N class 0.72
N0 23 (59.0%) 314 (62.1%)
N1 10 (25.6%) 149 (29.4%)
N2 5 (12.8%) 41 (8.1%)
N3 0 (0.0%) 2 (0.4%)
Missing 1 (2.6%) 0 (0.0%)
HER2 expression 0.046
Negative 37 (94.9%) 437 (86.4%)
Positive 1 (2.6%) 69 (13.6%)
Missing 1 (2.6%) 0 (0.0%)
Estrogen receptor expression 0.0062
Negative 1 (2.6%) 103 (20.4%)
Low 0 (0.0%) 18 (3.6%)
Moderate 0 (0.0%) 25 (4.9%)
High 37 (94.9%) 360 (71.1%)
Missing 1 (2.6%) 0 (0.0%)
Progesterone receptor expression 0.088
Negative 4 (10.3%) 148 (29.2%)
Low 4 (10.3%) 61 (12.1%)
Moderate 5 (12.8%) 57 (11.3%)
High 25 (61.5%) 240 (47.4%)
Missing 2 (5.1%) 0 (0.0%)
Ki-67 0.060
Negative 0 (0.0%) 32 (6.3%)
Low 14 (35.9%) 217 (43.1%)
Moderate 15 (38.5%) 116 (23.0%)
High 8 (20.5%) 139 (27.6%)
Missing 2 (5.1%) 2 (0.4%)
Adjuvant radiotherapy 0.23
No 8 (20.5%) 66 (13.4%)
Yes 31 (79.5%) 427 (86.6%)
Adjuvant chemotherapy 0.00070
No 27 (69.2%) 207 (40.2%)
Yes 12 (30.8%) 299 (59.1%)
Adjuvant endocrine therapy 0.015
No 7 (17.9%) 191 (37.7%)
Yes 32 (82.1%) 315 (62.3%)
Legend 2. Prognostic factors and adjuvant treatments of neuroendocrine breast carcinomas (NEBC) compared to the prospective set of ductal carcinomas. Primary
metastasized cancers have been excluded. Missing values have not been included to the analysis
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Survival analyses
The prognoses of non-metastatic NEBCs were compared
with the prospective cohort of ductal carcinomas (Fig. 1).
RFS was significantly worse in patients with NEBC com-
pared to ductal carcinomas (p = 0.0013). This difference was
reflected in DFS (p = 0.024), while no difference was
observed in DDFS. BCSS was not significantly different be-
tween the groups, but OS was shorter in patients with
NEBC (p = 0.0028).
Since Ki-67 expression is an essential prognostic factor
in ductal breast carcinomas and in gastrointestinal NEC,
we assessed its prognostic value in NEBC. Despite being
Fig. 1 Kaplan-Meier curves comparing neuroendocrine breast carcinomas and ductal breast carcinomas. Legend. Kaplan-Meier curves showing ipsilateral
relapse-free survival (a), distant disease-free survival (b), disease-free survival (c), breast cancer-specific survival (d) and overall survival (e) in non-metastatic
neuroendocrine breast carcinomas compared to a prospective set of local or locally advanced ductal breast carcinomas. Crosses indicate censored cases
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a strong predictor of poorer prognosis in ductal car-
cinomas (DFS p = 0.0006; BCSS p = 0.000003), Ki-67
did not have any prognostic significance in NEBC
(DFS p = 0.904; BCSS p = 0.729). Chromogranin expression
was not a significant predictor of any survival parameter.
Discussion
To the best of our knowledge, this is so far the largest
study assessing NEBC in the era of the current WHO cri-
teria [1]. Since gastrointestinal NEC is far more prevalent
than NEBC, WHO emphasizes the exclusion of extra-
mammary sites before the definite diagnosis of NEBC [1].
Adams et al. [4] recently analysed comprehensively the lit-
erature meeting the 2012 WHO criteria for primary neu-
roendocrine breast tumors. They found 58 published
articles, generating data for 108 cases including their own.
The mean size of primary tumors in their meta-analysis
was 3.7 cm, compared to 2.2 cm of the current study.
Lymph node involvement was recorded in 51% and dis-
tant metastases in 9% in the papers analysed by Adams et
al. in comparison with 39.6% and 9.3% within our mater-
ial, respectively. TNM data is therefore moderately in line
with the previous literature, although our material con-
sisted only cases from 2007, which may contribute to
smaller tumor size compared to data consisting also of
older cases collected by Adams et al. [4].
Tumor size and lymph node involvement of our NEBC
material were also comparable with the prospective set
of ductal carcinomas. This is supported by earlier study
of Wei et al. [6] in which NEBC had consistent staging
compared to a large cohort of invasive breast cancers
from Surveillance, Epidemiology and End Results data-
base. Surprisingly, we did not find Ki-67 as a predictor
of survival in NEBC, which, however, may be linked to
the restricted sample size and limited follow-up of the
current material.
The clinical outcome of NEBC has been poorly char-
acterized. Our data, even though having limited sample
size, suggest that NEBC patients may suffer from poorer
local control despite of adjuvant radiotherapy. Worse
RFS did not reflect to BCSS, although NEBC were less
often treated with adjuvant chemotherapy. Higher local
failure rate cannot be explained by the biological profile
of NEBC, which was less aggressive with more ER ex-
pression and less HER2 positivity. NEBC patients also
received adjuvant radiotherapy as frequently as the pa-
tients with ductal carcinomas. In line with the current
results, both the 10% local failure rate and high ER posi-
tivity/HER2 negativity in NEBC have been previously re-
ported by a retrospective study [6]. Although at the time
of the study, WHO diagnostic criteria from 2003 were
used [3]. In our material, worse OS of NEBC cases may
simply derive from older age of NEBC patient popula-
tion compared to the patients with ductal carcinoma.
The earliest analyses of NEBC suggested dismal prognosis
[12, 13] and also more recent retrospective studies have
suggested the NEBC patients (diagnosed according to the
WHO criteria from 2003) having shorter BCSS and OS
compared to the patients at the same stage [6, 14]. From
different histological subgroups, small/oat cell carcinoma
appears to be an adverse prognostic factor [15]. However,
when the most current NEBC classification is used and
tumor size and nodal involvement is limited, disease-
specific prognosis is rather good [4], which is suggested
also by our data. Larger material or meta-analysis would
still be required to more definitely conclude the impact of
NEBC differentiation to prognosis.
The reported or estimated incidence for NEBC has been
<1% of all breast cancers [1, 2]. There were on average 273
breast cancer cases per year in the hospital district of Oulu
University Hospital in 2009–2013 [16]. On average, 31
NEBC cases in 8.5 years in Oulu totals 3.6 cases per year.
This is 1.3% of all breast cancers being somewhat higher
compared to previously reported incidences. On the other
hand, in Helsinki University Hospital area there were on
average 1367 new breast cancer cases per year. Therefore
corresponding incidence for NEBC was 0.1% of all breast
cancers, 13-fold difference compared to the incidence in
Oulu University Hospital area. This is most likely due to
variation of neuroendocrine marker immunostaining preva-
lence between hospitals. Indeed, when in some studies neu-
roendocrine markers have been screened from unselected
breast carcinomas, up to 10.4% of all breast cancers showed
some synaptophysin or chromogranin A expression [17].
Conclusions
In summary, there seems to be a huge variation in the
incidence of NEBC within Finland, which probably can-
not be explained by true geographical variation. There is
a severe need for harmonization of NEBC diagnostics in
order to assess its pathobiological and clinical features in
more detail in larger and optimally in prospective stud-
ies. The use of chromogranin and synaptophysin immu-
nohistochemistry in a case of even lower suspicion of
NEBC could help to find these cancers more precisely.
Still the majority of neuroendocrine cancers have origin
outside breast and the exclusion on intermammary sites
is of the utmost importance. Although the best surgical
and oncological management of NEBC still remains un-
known, future studies should pay attention to possible
higher tendency of high local failure rates.
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